41 results on '"Markala D"'
Search Results
2. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy
- Author
-
Paschali, A., Panagiotidis, E., Triantafyllou, T., Palaska, V., Tsirou, K., Verrou, E., Υiannaki, E., Markala, D., Papanikolaou, A., Pouli, A., Konstantinidou, P., Chatzipavlidou, V., Terpos, E., and Katodritou, E.
- Published
- 2021
- Full Text
- View/download PDF
3. A STUDY OF MICROVESICLES IN THE ASSESSMENT OF THE THROMBOTIC MICROENVIRONMENT IN NEWLY DIAGNOSED DIABETES MELLITUS TYPE 2
- Author
-
Nikolaidou, B., Gkaliagkousi, E., Yiannaki, E., Gavriilaki, E., Anyfanti, P., Lazaridis, A., Triantafyllou, A., Zografou, I., Markala, D., and Douma, S.
- Published
- 2019
- Full Text
- View/download PDF
4. INTRACARDIAC CIRCULATING PLATELET MICROVESICLES ARE ASSOCIATED WITH THE SEVERITY OF CORONARY ARTERY DISEASE
- Author
-
Gkaliagkousi, E., Gavriilaki, E., Lazaridis, A., Nikolaidou, B., Triantafyllou, A., Anyfanti, P., Vasileiadis, I., Yiannaki, E., Markala, D., Zarifis, I., and Douma, S.
- Published
- 2019
- Full Text
- View/download PDF
5. INTRACARDIAC AND PERIPHERAL CIRCULATING ENDOTHELIAL MICROPARTICLES ARE ASSOCIATED WITH CENTRAL SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH CORONARY ARTERY DISEASE
- Author
-
Gkaliagkousi, E., Gavriilaki, E., Vasileiadis, I., Yannaki, E., Mavrogianni, A., Tsiakmakopoulos, K., Nikolaidou, B., Anyfanti, P., Markala, D., Zarifis, I., and Douma, S.
- Published
- 2018
- Full Text
- View/download PDF
6. [OP.8A.01] NEWLY DIAGNOSED DIABETES MELLITUS IS ASSOCIATED WITH INCREASED LEVELS OF ERYTHROCYTE MICROPARTICLES
- Author
-
Gkaliagkousi, E., Nikolaidou, B., Giannaki, E., Markala, D., Samalidou, A., Triantafyllou, A., Vamvakis, A., Gavriilaki, E., and Douma, S.
- Published
- 2017
- Full Text
- View/download PDF
7. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy
- Author
-
Paschali, A. Panagiotidis, E. Triantafyllou, T. Palaska, V. Tsirou, K. Verrou, E. Υiannaki, E. Markala, D. Papanikolaou, A. Pouli, A. Konstantinidou, P. Chatzipavlidou, V. Terpos, E. Katodritou, E.
- Abstract
Purpose: The investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy. Methods: We prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy. Results: SUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, β2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET. Conclusion: This study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2021
8. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy
- Author
-
Paschali, A., primary, Panagiotidis, E., additional, Triantafyllou, T., additional, Palaska, V., additional, Tsirou, K., additional, Verrou, E., additional, Υiannaki, E., additional, Markala, D., additional, Papanikolaou, A., additional, Pouli, A., additional, Konstantinidou, P., additional, Chatzipavlidou, V., additional, Terpos, E., additional, and Katodritou, E., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation
- Author
-
Gkaliagkousi, E., primary, Gavriilaki, E., additional, Yiannaki, E., additional, Vasileiadis, I., additional, Nikolaidou, B., additional, Lazaridis, A., additional, Dolgyras, P., additional, Grigoriadis, S., additional, Triantafyllou, A., additional, Anyfanti, P., additional, Markala, D., additional, Zarifis, I., additional, and Douma, S., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome
- Author
-
Hadjiaggelidou, C. Mandala, E. Terpos, E. Yiannaki, E. Markala, D. Triantafyllou, T. Papatheodorou, A. Gkastari, V. Verrou, E. Papanikolaou, A. Konstantinidou, P. Katodritou, E.
- Abstract
The exact role of regulatory T cells (Tregs) in multiple myeloma (MM) has not been yet determined. Data regarding alterations of Tregs during therapy with novel agents (NA), i.e., bortezomib and lenalidomide are conflicted and limited. We evaluated prospectively alterations of Tregs and searched for correlations with disease characteristics, response, and outcome in 29 patients with active MM treated with either bortezomib-dexamethasone (BD; 11 patients) or lenalidomide-dexamethasone (LenDex, 18 patients). Additionally, we recorded changes of lymphocytes subsets and cytokines related to Tregs function and MM biology, i.e., interleukin (IL) 6, 2, 17, and TGF-β. Compared with controls, patients had significantly higher median levels of Tregs%, IL-6, and IL-17 (p < 0.001). Median CD4 T and B cells frequencies were significantly lower, whereas CD8 T and natural killers were increased compared to controls. In BD group, no significant alterations of Tregs% were observed. Patients treated with LenDex, displayed a significant reduction of Tregs% (p < 0.001) especially those who achieved at least very good partial response (≥vgPR) (p = 0.04). Lymphocyte subsets or cytokines did not significantly change during therapy. In summary, Tregs% are higher in patients with active MM compared with controls, and they significantly decrease after treatment with LenDex but not with BD; After therapy with LenDex, Tregs reduction between baseline and major response correlated with achievement of ≥vgPR suggesting a possible predictive role, that may contribute to therapeutic strategy. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2019
11. ENDOTHELIAL MICROVESICLES ARE INCREASED IN UNTREATED NEWLY DIAGNOSED HYPERTENSION AND ARE ASSOCIATED WITH URINARY ALBUMIN EXCRETION
- Author
-
Lazaridis, A., primary, Gkaliagkousi, E., additional, Gavriilaki, E., additional, Nikolaidou, B., additional, Yiannaki, E., additional, Triantafyllou, A., additional, Anyfanti, P., additional, Dolgyras, P., additional, Markala, D., additional, and Douma, S., additional
- Published
- 2019
- Full Text
- View/download PDF
12. P426 Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?
- Author
-
Soufleris, K, primary, Kafalis, N, additional, Charalampidis, M, additional, Fasoulas, K, additional, Pilpilidis, I, additional, Lazaraki, G, additional, Tzilves, D, additional, and Markala, D, additional
- Published
- 2019
- Full Text
- View/download PDF
13. The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies
- Author
-
POLLER L, IBRAHIM S, KEOWN M, PATTISON A, JESPERSEN J, EUROPEAN ACTION ON A.N.T.I.C.O.A.G.U.L.A.T.I.O.N. COLLABORATORS: MARUN S, MUNTEAN W, ASPÖCK G, BAILLEUL E, WIJNS W, MICHEL T, JOCHMANS K, CHATELAIN B, MARCELIS L, NIJS AN, JOHNSTON M, KYNDE K, SYRÄJLÄ M, SAVOLAINEN ER, IVASKA K, RAJAMÄKI A, VANHARANTA R, JUHAN I, AILLAUD MF, GUILLIN MC, HUISSE MG, SIE P, LECOMPTE T, SCHMITT Y, HARENBERG J, PLESCH W, ARONIS S, THEODOSSIADES G, TSOUKANAS B, MARKALA D, DITSA M, CAHILL M, MADDEN M, FITZGERALD H, MCCARTHY D, COLLINS B, ROONEY S, NAPARSTEK E, MARONGIU F, ERBA N, TESTA S, MARIANI G, POTÌ R, MANNUCCI PM, TRIPODI A, BADER R, PENGO V, GRESELE P, D'INCÀ M, AGENO W, TOSETTO A, HENSGENS HE, IDEMA RN, OOSTERHOUT DH, MULDER AB, HAMULYAK K, VD DUSSEN H, MUSIAL J, GAGO T, PALMEIRO A, CAMPOS M, MARQUES DIAS DA, CUNHA MONTEIRO Á, ANGELA CUNHA M, DE GAIA WN, PETERNEL P, STEGNAR M, FONTCUBERTA J, BORRELL M, REVERTER JC, SANTASUSANA PD, LOPEZ FERNANDEZ MF, MONTERO J, RIBERA CASADO C, VICENTE V, EDLUND B, EGBERG N, LÄMMLE B, ALBERIO L, DE MOERLOOSE P, REBER G, MACHIN SJ, MACKIE I, LAWRIE A, LUCKIT J, SHANKS D, DOLAN G, FLAHERTY T, LUDLAM CA, WALKER ID, LAWSON DE, TRISCOTT M, MARLAR RA, HEIT JA, WATZKE H, WEISSER B, GALLUS AS, OSMOND J, CORNET I, MUNSTER AM, LEED B, CHILLOU C, DEFARD M, HORELLOU MH, HALKIN H, LOEBSTEIN R, KIRGNER I, DENTALI F, TRAPANI LOMBARDO V, SOTTILOTTA G, CONSIGLIO P, DE MICHELE S, MOIA M, CARPENEDO M, OLIVIERO B, MANOTTI C, TASSONI MI, PALARETI G, BRUSI C, LEGNANI C, PEGORARO C, ANDRIANI C, GRAZIA CIRIGLIANO M, RIBALDI E, ABBATE R, POLI D, PERRICONE C, SCHIAVULI M, CASIERA C, LUPONE MR, ROSSI E, CRIVELLI S, BIROLINI A, PARENTE F, MIGLIETTA AM, CAMPOBASSO M, SYDOR W, KREVEL B, FERNANDEZ MA, LOZANO M, SHIACH C, BOWYER C, CHARLES F., PALARETI, GUALTIERO, COSMI, BENILDE, POLLER L, IBRAHIM S, KEOWN M, PATTISON A, JESPERSEN J, EUROPEAN ACTION ON ANTICOAGULATION. COLLABORATORS: MARUN S, MUNTEAN W, ASPÖCK G, BAILLEUL E, WIJNS W, MICHEL T, JOCHMANS K, CHATELAIN B, MARCELIS L, NIJS AN, JOHNSTON M, KYNDE K, SYRÄJLÄ M, SAVOLAINEN ER, IVASKA K, RAJAMÄKI A, VANHARANTA R, JUHAN I, AILLAUD MF, GUILLIN MC, HUISSE MG, SIE P, LECOMPTE T, SCHMITT Y, HARENBERG J, PLESCH W, ARONIS S, THEODOSSIADES G, TSOUKANAS B, MARKALA D, DITSA M, CAHILL M, MADDEN M, FITZGERALD H, MCCARTHY D, COLLINS B, ROONEY S, NAPARSTEK E, PALARETI G, MARONGIU F, ERBA N, TESTA S, MARIANI G, POTÌ R, MANNUCCI PM, TRIPODI A, BADER R, PENGO V, GRESELE P, D'INCÀ M, AGENO W, TOSETTO A, HENSGENS HE, IDEMA RN, OOSTERHOUT DH, MULDER AB, HAMULYAK K, VD DUSSEN H, MUSIAL J, GAGO T, PALMEIRO A, CAMPOS M, MARQUES-DIAS DA, CUNHA MONTEIRO Á, ANGELA CUNHA M, DE GAIA WN, PETERNEL P, STEGNAR M, FONTCUBERTA J, BORRELL M, REVERTER JC, SANTASUSANA PD, LOPEZ-FERNANDEZ MF, MONTERO J, RIBERA CASADO C, VICENTE V, EDLUND B, EGBERG N, LÄMMLE B, ALBERIO L, DE MOERLOOSE P, REBER G, MACHIN SJ, MACKIE I, LAWRIE A, LUCKIT J, SHANKS D, DOLAN G, FLAHERTY T, LUDLAM CA, WALKER ID, LAWSON DE, TRISCOTT M, MARLAR RA, HEIT JA, WATZKE H, WEISSER B, GALLUS AS, OSMOND J, CORNET I, MUNSTER AM, LEED B, CHILLOU C, DEFARD M, HORELLOU MH, HALKIN H, LOEBSTEIN R, KIRGNER I, DENTALI F, TRAPANI LOMBARDO V, SOTTILOTTA G, CONSIGLIO P, DE MICHELE S, MOIA M, CARPENEDO M, OLIVIERO B, MANOTTI C, TASSONI MI, COSMI B, BRUSI C, LEGNANI C, PEGORARO C, ANDRIANI C, GRAZIA CIRIGLIANO M, RIBALDI E, ABBATE R, POLI D, PERRICONE C, SCHIAVULI M, CASIERA C, LUPONE MR, ROSSI E, CRIVELLI S, BIROLINI A, PARENTE F, MIGLIETTA AM, CAMPOBASSO M, SYDOR W, KREVEL B, FERNANDEZ MA, LOZANO M, SHIACH C, BOWYER C, CHARLES F., Interne Geneeskunde, Biochemie, and RS: CARIM School for Cardiovascular Diseases
- Subjects
INR correction ,endocrine system ,medicine.medical_specialty ,coagulometers ,Prothrombin Time/*standard ,Reproducibility of Result ,PT ,World Health Organization ,International Normalized Ratio/*standard ,Thromboplastin ,Automation ,Laboratory/standard ,ECAA plasmas ,Predictive Value of Tests ,health services administration ,medicine ,Animals ,Humans ,heterocyclic compounds ,International Normalized Ratio ,cardiovascular diseases ,thromboplastins ,Blood Coagulation ,Reference standards ,Mathematics ,Automation, Laboratory ,Observer Variation ,Prothrombin time ,Analysis of Variance ,medicine.diagnostic_test ,business.industry ,fungi ,Reproducibility of Results ,Hematology ,Reference Standards ,Surgery ,INR Line ,Multicenter study ,Calibration ,Linear Models ,Prothrombin Time ,Cattle ,Rabbits ,Observer variation ,Nuclear medicine ,business - Abstract
The WHO scheme for prothrombin time (PT) standardization has been limited in application, because of its difficulties in implementation, particularly the need for mandatory manual PT testing and for local provision of thromboplastin international reference preparations (IRP).The value of a new simpler procedure to derive international normalized ratio (INR), the PT/INR Line, based on only five European Concerted Action on Anticoagulation (ECAA) calibrant plasmas certified by experienced centres has been assessed in two independent exercises using a range of commercial thromboplastins and coagulometers. INRs were compared with manual certified values with thromboplastin IRP from expert centres and in the second study also with INRs from local ISI calibrations.In the first study with the PT/INR Line, 8.7% deviation from certified INRs was reduced to 1.1% with human reagents, and from 7.0% to 2.6% with rabbit reagents. In the second study, deviation was reduced from 11.2% to 0.4% with human reagents by both local ISI calibration and the PT/INR Line. With rabbit reagents, 10.4% deviation was reduced to 1.1% with both procedures; 4.9% deviation was reduced to 0.5% with bovine/combined reagents with local ISI calibrations and to 2.9% with the PT/INR Line. Mean INR dispersion was reduced with all thromboplastins and automated systems using the PT/INR Line.The procedure using the PT/INR Line provides reliable INR derivation without the need for WHO ISI calibration across the range of locally used commercial thromboplastins and automated PT systems included in two independent international studies.? 2010 International Society on Thrombosis and Haemostasis.
- Published
- 2011
14. Endotoxin-induced disseminated intravascular coagulation (DIC) in rabbits: Crocetin administratioin prevents plasminogen activator activity (PAA) decrease in kidneys
- Author
-
Tsantarliotou, M., Poutahidis Th, Markala, D., Kazakos, G., Sapanidou, V., Lavrentiadou, S., Zervos, I., Taitzoglou, I., and Sinakos, Z.
- Published
- 2011
- Full Text
- View/download PDF
15. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
- Author
-
Katodritou, E., Gastari, V., Verrou, E., Hadjiaggelidou, C., Varthaliti, M., Georgiadou, S., Laschos, K., Xirou, P., Yiannaki, E., Constantinou, N., Markala, D., and Zervas, K.
- Published
- 2009
- Full Text
- View/download PDF
16. Platelet Activation in Essential Hypertension During Exercise: Pre- and Post-Treatment Changes With an Angiotensin II Receptor Blocker
- Author
-
Gkaliagkousi, E., primary, Gavriilaki, E., additional, Yiannaki, E., additional, Markala, D., additional, Papadopoulos, N., additional, Triantafyllou, A., additional, Anyfanti, P., additional, Petidis, K., additional, Garypidou, V., additional, Doumas, M., additional, Ferro, A., additional, and Douma, S., additional
- Published
- 2013
- Full Text
- View/download PDF
17. Protein tyrosine kinase inhibitor, genistein, enhances apoptosis and cell cycle arrest in K562 cells treated with g-irradiation
- Author
-
Papazisis, K. T., Zambouli, D., Kimoundri, O. T., Papadakis, E. S., Vala, V., Geromichalos, G. D., Voyatzi, S., Markala, D., Destouni, E., and Boutis, L.
- Published
- 2000
- Full Text
- View/download PDF
18. Programmed Cell Death Induced in WEHI 13 var Cultured Fibroblasts by Exposure to Dental Composite Resin Eluates.
- Author
-
Bakopoulou, A., Tsiftsoglou, A., Galaktidou, G., Markala, D., Triviai, I., and Garefis, P.
- Subjects
DENTAL resins ,CELL death ,APOPTOSIS ,NECROSIS ,DENTAL materials ,FIBROBLASTS ,CELL-mediated cytotoxicity ,ACRIDINE ,PHOSPHATIDYLSERINES ,CELL membranes - Abstract
Purpose: Earlier studies have shown that in vitro exposure to single compounds released from composite resins is able to induce cell death via apoptosis and/or necrosis. The purpose of this study was to evaluate the effect of eluates of commercially available composites used for direct (Tetric Ceram/Ivoclar-Vivadent, Simile/Pentron, Filtek Z-250/3M ESPE) and indirect restorations (Adoro/Ivoclar-Vivadent and Conquest Sculpture/Pentron) on the type of cell death of cultured WEHI 13 var fibroblasts. Materials and Methods: Cells exposed to eluates of the materials were assayed by MTT for cytotoxicity, flow cytometry for cell death, biochemically for caspase-3 activation and fluorescent microscopy with Acridine Orange for morphological changes. Results: The 3 direct composite resin eluates induced extensive apoptosis characterized by externalization of phosphatidylserine at the cell surface, activation and positive cytoplasmic expression of caspase-3, and chromatin disintegration. This was accompanied by morphological changes, such as cell enlargement micromultinucleation and membrane blebbing. On the other hand, the other 2 composite resins for indirect restorations were much less cytotoxic in all biological endpoints investigated. Conclusion: These findings suggest that composite resins used for direct and indirect restorations differ extensively in their cytotoxic potential and their ability to induce programmed cell death. This signifies the role of composition and polymerization of these 2 classes of biomaterials with respect to their biologic behavior. [ABSTRACT FROM AUTHOR]
- Published
- 2008
19. International staging system vs. Durie-Salmon staging system in multiple myeloma: Evaluation of their prognostic significance
- Author
-
Mihou, D., Elisavet Georgiou, Verrou, E., Banti, A., Chelis, L., Markala, D., Kaloutsi, V., and Zervas, K.
20. T-regulatory cells are reduced after treatment with lenalidomide, but not bortezomib, in multiple myeloma
- Author
-
Hadjiaggelidou, C., Mandala, E., Terpos, E., Markala, D., Yiannaki, E., Papatheodorou, A., Ilonidis, G., Garipidou, V., Kaiafa, G., Vasileios Perifanis, Vakalopoulou, S., Garifalos, A., and Katodritou, E.
21. Circulating microvesicles across a population with various degree of cardiovascular burden are associated with systolic blood pressure.
- Author
-
Gavriilaki E, Lazaridis A, Anyfanti P, Yiannaki E, Dolgyras P, Nikolaidou B, Vasileiadis I, Alexandrou ME, Margouta A, Markala D, Zarifis I, Sarafidis P, Doumas M, and Gkaliagkousi E
- Subjects
- Humans, Blood Pressure, Heart, Essential Hypertension, Coronary Artery Disease diagnosis, Coronary Artery Disease etiology, Kidney Failure, Chronic diagnosis
- Abstract
Circulating microvesicles (MVs) have been studied in heterogeneous, divergent, and rather small patient populations with cardiovascular risk . Therefore, we measured endothelial (EMVs), platelet (PMVs) and erythrocyte (RMVs) MVs in patients with divergent cardiovascular risk. We then compared them to coronary artery disease (CAD) and healthy subjects and identified independent MVs' predictors. We enrolled consecutive patients from our Cardiology, Hypertension, Diabetic, Rheumatic, and Nephrology Outpatient Units with MVs measurements. Central blood pressure (BP) was measured by either applanation tonometry or Mobil-O-graph device, while MVs by a standardized flow cytometry protocol. We studied 369 participants with increased cardiovascular risk: 63 with high cardiovascular risk (47 diabetes mellitus type II/DM and 16 end-stage renal disease/ESRD), 92 with chronic inflammatory disorders and 73 with untreated essential hypertension/UEH. We further included 53 subjects with CAD and 87 otherwise healthy individuals. All MVs were lower in patients with increased cardiovascular risk compared to CAD, showing predictive value with high sensitivity and specificity. Furthermore, PMVs and EMVs were increased in patients with cardiovascular risk compared to healthy individuals. DM and ESRD patients had increased EMVs versus UEH and chronic inflammatory disorders. In the whole study population, RMVs were associated only with history of essential hypertension. In multivariate analysis, systolic BP predicted PMVs. Aage, systolic BP, and DM predicted EMVs. In a large population of patients with divergent cardiovascular risk, MVs are independently associated with systolic blood pressure., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
22. A study of endothelial and platelet microvesicles across different hypertension phenotypes.
- Author
-
Lazaridis A, Gavriilaki E, Nikolaidou B, Yiannaki E, Dolgyras P, Anyfanti P, Triantafyllou A, Koletsos N, Tzimos C, Markala D, Douma S, and Gkaliagkousi E
- Subjects
- Humans, Inflammation, Phenotype, Cell-Derived Microparticles, Hypertension diagnosis, Thrombosis
- Abstract
Rather than being mere biomarkers reflecting generalized vascular injury, endothelial- (EMVs) and platelet-derived (PMVs) microvesicles have emerged as potent regulators of intercellular communication with significant biologic effects in vascular homeostasis and several pathophysiological responses including inflammation and thrombosis. So far, studies in hypertension are scarce, whereas no studies exist in masked hypertension (MH). We measured EMVs and PMVs in untreated, newly diagnosed hypertensives (HTs) and MHs compared to normotensive controls (NTs), and associated them with various cardiovascular risk factors. Sustained hypertension (SHT) and MH were defined according to standard blood pressure (BP) criteria. All HTs were free of cardiovascular disease and medications. Microvesicles' quantitation and detection were performed by flow cytometry by using cell-specific antibodies and corresponding isotypes (anti-CD105 and anti-CD144 for EMVs, anti-CD42a for PMVs, and Annexin V-fluorescein isothiocyanate for all microvesicles). In this study, we included 59 HTs (44 SHTs and 15 MHs) and 27 NTs. HTs had significantly elevated EMVs (p = 0.004), but not PMVs compared to NTs. MHs had significantly elevated EMVs compared to NTs (p = 0.012) but not compared to SHTs. Furthermore, EMVs significantly correlated with ambulatory (r = 0.214-0.284), central BP (r = 0.247-0.262), and total vascular resistance (r = 0.327-0.361). EMVs are increased not only in SHTs but also in MHs, a hypertension phenotype with a cardiovascular risk close to SHT. EMVs have emerged as active contributors to thromboinflammation and vascular damage and may explain, in part, the adverse cardiovascular profile of SHTs and MHs., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
23. Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Gavriilaki E, Sakellari I, Anyfanti P, Batsis I, Vardi A, Bousiou Z, Lazaridis A, Nikolaidou B, Zarifis I, Masmanidou M, Yiannaki E, Markala D, Anagnostopoulos A, Douma S, and Gkaliagkousi E
- Subjects
- Adolescent, Adult, Cancer Survivors statistics & numerical data, Cardiovascular Diseases etiology, Case-Control Studies, Female, Graft vs Host Disease pathology, Heart Disease Risk Factors, Humans, Male, Middle Aged, Transplantation, Homologous, Young Adult, Blood Coagulation Factors, Cardiovascular Diseases diagnosis, Cell-Derived Microparticles pathology, Endothelium, Vascular injuries, Graft vs Host Disease etiology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
(1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January-December 2019). Circulating microvesicles (MVs) of different cellular origins (platelet, erythrocyte, and endothelial) were measured by a standardized flow cytometry protocol as novel markers of vascular injury and pro-coagulant activity. (3) Results: we recruited 45 survivors after a median of 2.3 (range 1.1-13.2) years from alloHCT, and 45 controls. The majority of patients suffered from acute (44%) and/or chronic (66%) graft-versus-host disease (GVHD). Although the two groups were matched for traditional cardiovascular risk factors, alloHCT survivors showed significantly increased platelet and erythrocyte MVs compared to controls. Within alloHCT survivors, erythrocyte MVs were significantly increased in patients with a previous history of thrombotic microangiopathy. Interestingly, endothelial MVs were significantly increased only in alloHCT recipients of a myeloablative conditioning. Furthermore, MVs of different origins showed a positive association with each other. (4) Conclusions: endothelial dysfunction and increased thrombotic risk are evident in alloHCT recipients long after alloHCT, independently of traditional cardiovascular risk factors. An apparent synergism of these pathophysiological processes may be strongly involved in the subsequent establishment of cardiovascular disease.
- Published
- 2020
- Full Text
- View/download PDF
24. Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response.
- Author
-
Hadjiaggelidou C, Vadikolia C, Verrou E, Yiannaki E, Triantafyllou T, Palaska V, Keramidioti K, Tsirou K, Papanikolaou A, Markala D, Konstantinidou P, and Katodritou E
- Abstract
Competing Interests: The authors have no conflicts of interest to disclose.
- Published
- 2020
- Full Text
- View/download PDF
25. Endothelial Microvesicles Circulating in Peripheral and Coronary Circulation Are Associated With Central Blood Pressure in Coronary Artery Disease.
- Author
-
Gkaliagkousi E, Gavriilaki E, Vasileiadis I, Nikolaidou B, Yiannaki E, Lazaridis A, Triantafyllou A, Anyfanti P, Markala D, Zarifis I, and Douma S
- Subjects
- Acute Coronary Syndrome blood, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome physiopathology, Aged, Case-Control Studies, Coronary Angiography, Coronary Artery Disease blood, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease physiopathology, Female, Flow Cytometry, Humans, Male, Middle Aged, Non-ST Elevated Myocardial Infarction blood, Non-ST Elevated Myocardial Infarction diagnostic imaging, Non-ST Elevated Myocardial Infarction physiopathology, ST Elevation Myocardial Infarction blood, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction physiopathology, Acute Coronary Syndrome pathology, Cell-Derived Microparticles pathology, Coronary Artery Disease pathology, Coronary Circulation, Endothelial Cells pathology, Non-ST Elevated Myocardial Infarction pathology, ST Elevation Myocardial Infarction pathology
- Abstract
Background: Endothelial microvesicles (EMVs) have emerged as markers of endothelial injury. However, little is known about their levels in the coronary circulation of acute coronary syndrome (ACS) and stable coronary artery disease (CAD). We hypothesized that ACS patients exhibit a more pronounced increase of EMVs both in the peripheral and coronary circulation when compared with CAD. We also investigated possible associations of EMVs with markers preclinical target organ damage., Methods: We enrolled consecutive eligible patients undergoing coronary angiography. Blood samples were collected from the stem of the left coronary artery and the femoral artery. ΕMVs were measured by a standardized flow cytometry protocol. Central systolic blood pressure (cSBP) was measured invasively and patients' history was recorded., Results: CAD patients exhibited increased levels of EMVs compared with controls. When patients with ACS and stable CAD were compared, the former had significantly increased EMVs in both coronary and peripheral circulation. Importantly, both ACS and CAD patients exhibited increased levels of EMVs in the coronary circulation compared with periphery. In addition, EMVs were associated with cSBP., Conclusions: EMVs emerge as novel markers of ongoing underlying vascular damage, further augmenting the vicious cycle of inflammation and thrombosis mainly in ACS but also in stable CAD., (© American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
26. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus.
- Author
-
Gkaliagkousi E, Nikolaidou B, Gavriilaki E, Lazaridis A, Yiannaki E, Anyfanti P, Zografou I, Markala D, and Douma S
- Subjects
- Adult, Aged, Biomarkers blood, Blood Glucose metabolism, Blood Platelets metabolism, Case-Control Studies, Cell-Derived Microparticles metabolism, Cross-Sectional Studies, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Erythrocytes metabolism, Female, Glycated Hemoglobin metabolism, Glycation End Products, Advanced blood, Humans, Male, Middle Aged, Thrombosis, Blood Platelets pathology, Cell-Derived Microparticles pathology, Diabetes Mellitus, Type 2 pathology, Erythrocytes pathology
- Abstract
Aim: To investigate the thrombotic microenvironment in early stages of type 2 diabetes mellitus measuring platelet-derived, endothelial-derived and erythrocyte-derived microvesicles., Methods: We recruited 50 newly diagnosed type 2 diabetes mellitus patients who did not receive glucose-lowering treatment except for metformin and 25 matched non-type 2 diabetes mellitus volunteers. Microvesicles were measured with flow cytometry, glycated haemoglobin with high-performance liquid chromatography and advanced glycation end products with enzyme-linked immunosorbent assay., Results: Type 2 diabetes mellitus patients showed significantly higher levels of platelet-derived microvesicles [195/μL (115-409) vs 110/μL (73-150), p = 0.001] and erythrocyte-derived microvesicles [26/μL (9-100) vs 9/μL (4-25), p = 0.007] compared to non-type 2 diabetes mellitus individuals. Platelet-derived microvesicles were positively associated with fasting blood glucose ( p = 0.026) and glycated haemoglobin ( p = 0.002). Erythrocyte-derived microvesicles were also positively associated with fasting blood glucose ( p = 0.018) but not with glycated haemoglobin ( p = 0.193). No significant association was observed between platelet-derived microvesicles ( p = 0.126) or erythrocyte-derived microvesicles ( p = 0.857) and advanced glycation end products. Erythrocyte-derived microvesicles predicted the presence of type 2 diabetes mellitus, independently of platelet-derived microvesicles., Conclusion: In newly diagnosed type 2 diabetes mellitus, ongoing atherothrombosis is evident during the early stages as evidenced by increased microvesicles levels. Furthermore, the association with glycemic profile suggests that microvesicles represent not only a novel mechanism by which hyperglycemia amplifies thrombotic tendency in type 2 diabetes mellitus but also early markers of thrombosis highlighting the need for earlier management of hyperglycemia.
- Published
- 2019
- Full Text
- View/download PDF
27. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
- Author
-
Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, Papatheodorou A, Gkastari V, Verrou E, Papanikolaou A, Konstantinidou P, and Katodritou E
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols pharmacology, Bortezomib administration & dosage, Bortezomib pharmacology, Cytokines blood, Dexamethasone administration & dosage, Dexamethasone pharmacology, Female, Humans, Lenalidomide administration & dosage, Lenalidomide pharmacology, Lymphocyte Count, Male, Middle Aged, Multiple Myeloma blood, Multiple Myeloma drug therapy, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets metabolism, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory metabolism, Transforming Growth Factor beta analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma immunology, T-Lymphocyte Subsets immunology, T-Lymphocytes, Regulatory immunology
- Abstract
The exact role of regulatory T cells (Tregs) in multiple myeloma (MM) has not been yet determined. Data regarding alterations of Tregs during therapy with novel agents (NA), i.e., bortezomib and lenalidomide are conflicted and limited. We evaluated prospectively alterations of Tregs and searched for correlations with disease characteristics, response, and outcome in 29 patients with active MM treated with either bortezomib-dexamethasone (BD; 11 patients) or lenalidomide-dexamethasone (LenDex, 18 patients). Additionally, we recorded changes of lymphocytes subsets and cytokines related to Tregs function and MM biology, i.e., interleukin (IL) 6, 2, 17, and TGF-β. Compared with controls, patients had significantly higher median levels of Tregs%, IL-6, and IL-17 (p < 0.001). Median CD4 T and B cells frequencies were significantly lower, whereas CD8 T and natural killers were increased compared to controls. In BD group, no significant alterations of Tregs% were observed. Patients treated with LenDex, displayed a significant reduction of Tregs% (p < 0.001) especially those who achieved at least very good partial response (≥vgPR) (p = 0.04). Lymphocyte subsets or cytokines did not significantly change during therapy. In summary, Tregs% are higher in patients with active MM compared with controls, and they significantly decrease after treatment with LenDex but not with BD; After therapy with LenDex, Tregs reduction between baseline and major response correlated with achievement of ≥vgPR suggesting a possible predictive role, that may contribute to therapeutic strategy.
- Published
- 2019
- Full Text
- View/download PDF
28. Blastic plasmacytoid dendritic cell neoplasm: single-center experience with two cases in one year.
- Author
-
Agapidou A, Vakalopoulou S, Markala D, Chadjiaggelidou C, Tzimou M, Papadopoulou T, and Garypidou V
- Published
- 2014
- Full Text
- View/download PDF
29. Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.
- Author
-
Gkaliagkousi E, Gavriilaki E, Yiannaki E, Markala D, Papadopoulos N, Triantafyllou A, Anyfanti P, Petidis K, Garypidou V, Doumas M, Ferro A, and Douma S
- Subjects
- Adult, Antihypertensive Agents therapeutic use, Carotid Intima-Media Thickness, Essential Hypertension, Female, Humans, Male, Middle Aged, Valine therapeutic use, Valsartan, Angiotensin Receptor Antagonists therapeutic use, Exercise physiology, Hypertension physiopathology, Platelet Activation drug effects, Tetrazoles therapeutic use, Valine analogs & derivatives
- Abstract
Background: Acute exercise may exert deleterious effects on the cardiovascular system through a variety of pathophysiological mechanisms, including increased platelet activation. However, the degree of exercise-induced platelet activation in untreated hypertensive (UH) individuals as compared with normotensive (NT) individuals has yet to be established. Furthermore, the effect of antihypertensive treatment on exercise-induced platelet activation in essential hypertension (EH) remains unknown., Methods: Study 1 consisted of 30 UH and 15 NT subjects. UH subjects who received treatment were included in study 2 and were followed-up after a 3-month treatment period with an angiotensin II receptor blocker (ARB; valsartan). Circulating monocyte-platelet aggregates (MPA) and platelet P-selectin were measured as platelet activation markers at baseline, immediately after a treadmill exercise test, and 10, 30, and 90 minutes later., Results: Maximal platelet activation was observed at 10 minutes after peak exercise in both groups. In UH subjects, MPA levels remained increased at 30 minutes after peak exercise, despite BP fall to baseline levels. MPA levels were significantly higher in UH subjects than NT subjects at maximal exercise and at 10 and 30 minutes of recovery. Post-treatment MPA levels increased significantly only at 10 minutes into recovery and were similar to those of NT subjects., Conclusions: Acute high-intensity exercise exaggerates platelet activation in untreated patients with EH compared with NT individuals. Angiotensin II receptor blockade with adequate BP control greatly improves exercise-induced platelet activation in EH. Further studies are needed to clarify whether this phenomenon depends purely on BP lowering or benefits also from the pleiotropic effects of ARBs.
- Published
- 2014
- Full Text
- View/download PDF
30. Concurrent presentation of nodal myeloid sarcoma and bone marrow chronic lymphocytic leukemia/small lymphocytic lymphoma: a unique association.
- Author
-
Perifanis V, Diamantidis MD, Chalvatzi K, Kaloutsi V, Markala D, Voulgaridou V, Pantelidou P, Pavlidis A, Stavrou G, and Kaiafa G
- Subjects
- Aged, Antigens, Surface metabolism, Biopsy, Female, Humans, Immunophenotyping, Lymph Nodes pathology, Bone Marrow pathology, Leukemia, Lymphocytic, Chronic, B-Cell complications, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Sarcoma, Myeloid complications, Sarcoma, Myeloid diagnosis
- Abstract
Myeloid sarcoma (MS), previously known as granulocytic sarcoma, is a rare, localized, tumor mass composed of myeloid precursor cells, with or without maturation, and occurring at an anatomical site other than the bone marrow (BM). Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in contrast, is a B-cell hematological malignancy. We describe the first reported case of concurrent presentation of nodal MS and of BM CLL/SLL in the same patient. Fatal leukemic central nervous system infiltration was the final outcome. We provide possible explanations and investigate the pathophysiology of this unique, previously unreported co-morbidity.
- Published
- 2014
- Full Text
- View/download PDF
31. Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells.
- Author
-
Eleftheriadis T, Pissas G, Yiannaki E, Markala D, Arampatzis S, Antoniadi G, Liakopoulos V, and Stefanidis I
- Subjects
- Adult, Citric Acid Cycle drug effects, Enzyme Activation drug effects, Glucose Transporter Type 1 genetics, Glucose Transporter Type 1 metabolism, Glycolysis, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism, Lymphocyte Culture Test, Mixed, Male, Mechanistic Target of Rapamycin Complex 1, Multiprotein Complexes metabolism, Protein Serine-Threonine Kinases metabolism, T-Lymphocyte Subsets drug effects, TOR Serine-Threonine Kinases metabolism, Tryptophan analogs & derivatives, Tryptophan metabolism, Tryptophan pharmacology, Glucose metabolism, Indoleamine-Pyrrole 2,3,-Dioxygenase antagonists & inhibitors, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism
- Abstract
Indoleamine 2,3-dioxygenase (IDO) suppresses adaptive immunity. T-cell proliferation and differentiation to effector cells require increased glucose consumption, aerobic glycolysis and glutaminolysis. The effect of IDO on the above metabolic pathways was evaluated in alloreactive T-cells. Mixed lymphocyte reaction (MLR) in the presence or not of the IDO inhibitor, 1-methyl-dl-tryptophan (1-MT), was used. In MLRs, 1-MT decreased tryptophan consumption, increased cell proliferation, glucose influx and lactate production, whereas it decreased tricarboxylic acid cycle activity. In T-cells, from the two pathways that could sense tryptophan depletion, i.e. general control nonrepressed 2 (GCN2) kinase and mammalian target of rapamycin complex 1, 1-MT reduced only the activity of the GCN2 kinase. Additionally 1-MT treatment of MLRs altered the expression and/or the phosphorylation state of glucose transporter-1 and of key enzymes involved in glucose metabolism and glutaminolysis in alloreactive T-cells in a way that favors glucose influx, aerobic glycolysis and glutaminolysis. Thus in alloreactive T-cells, IDO through activation of the GCN2 kinase, decreases glucose influx and alters key enzymes involved in metabolism, decreasing aerobic glycolysis and glutaminolysis. Acting in such a way, IDO could be considered as a constraining factor for alloreactive T-cell proliferation and differentiation to effector T-cell subtypes., (Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
32. Crocetin administration ameliorates endotoxin-induced disseminated intravascular coagulation in rabbits.
- Author
-
Tsantarliotou MP, Poutahidis T, Markala D, Kazakos G, Sapanidou V, Lavrentiadou S, Zervos I, Taitzoglou I, and Sinakos Z
- Subjects
- Animals, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation chemically induced, Endotoxins, Fibrinogen metabolism, Male, Platelet Count, Protein C metabolism, Rabbits, Thrombin metabolism, Vitamin A analogs & derivatives, Antioxidants pharmacology, Blood Platelets drug effects, Carotenoids pharmacology, Disseminated Intravascular Coagulation drug therapy, Fibrinolytic Agents pharmacology
- Abstract
Disseminated intravascular coagulation (DIC), a life-threatening secondary complication in several diseases, is characterized by large amounts of thrombin that lead to fibrin deposition and microthrombus formation throughout the microcirculation. Recent in-vitro studies suggest that crocin, crocetin or safranal, carotenoid constituents of the spice Crocus sativus L. (saffron), have antithrombotic properties, especially anti-Xa activity. The present study was designed to evaluate the effect of crocetin on thrombosis procedure using a rabbit model of bacterial endotoxin-induced DIC. Crocetin administration (3 mg/kg), 30 min before the beginning of endotoxin infusion, improved DIC-related haemostatic indices such as platelet blood counts (P≤ 0.05), blood plasma fibrinogen and protein C concentration (P≤ 0.05). In addition, it ameliorated DIC-associated disease and fibrin deposition in the glomeruli (P≤ 0.05). These results indicate that crocetin reveals a preventive antithrombotic role in vivo and prescribe further investigation on the possibility of developing crocetin-based DIC treatment modalities.
- Published
- 2013
- Full Text
- View/download PDF
33. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients.
- Author
-
Eleftheriadis T, Kartsios C, Yiannaki E, Antoniadi G, Kazila P, Pliakos K, Liakopoulos V, and Markala D
- Subjects
- Adult, Aged, Aging immunology, C-Reactive Protein analysis, Chronic Disease, Female, Humans, Interleukin-6 blood, Male, Middle Aged, CD3 Complex analysis, Inflammation etiology, Kidney Failure, Chronic immunology, Killer Cells, Natural immunology, Receptors, Antigen, T-Cell analysis, Receptors, IgG analysis, Renal Dialysis
- Abstract
Aim: Clinical and experimental data indicate a deficient immune response in haemodialysis (HD) patients. Natural killer-like (NKL) T cells express on their surface both the T-cell antigen receptor (TCR) and a diverse set of NK-cell receptors (NKR) and share properties of both T cells and NK cells. zeta-Chain phosphorylation is an early event that follows TCR activation or some NKR activation. The zeta-chain of both T cell and NK cells is downregulated in many chronic inflammatory states, HD included. In the present study, NKL T-cell percentage and zeta-chain expression in HD patients were evaluated., Methods: Thirty-three stable HD patients and 30 healthy volunteers were enrolled into the study. NKL T-cell percentage and NKL T-cell zeta-chain mean fluorescence intensity (MFI) were evaluated with flow cytometry. The inflammatory markers C-reactive protein, interleukin-6 and tumour necrosis factor-alpha were measured in the serum by means of enzyme-linked immunosorbent assay., Results: All the evaluated markers of inflammation were increased in HD patients. In these patients, NKL T-cell percentage (1.71 +/- 1.69% vs 3.94 +/- 3.86%) and zeta-chain MFI (3.66 +/- 2.79 vs 7.03 +/- 7.91) were decreased., Conclusions: NKL T-cell percentage and zeta-chain expression is decreased in HD patients. Taking into consideration the continuously increasing age of the HD patients and that normally NKL T-cell numbers increase with age counteracting the impaired T-cell and NK-cell function accompanying advancing age, the above NKL T-cell disturbances could contribute to the impaired immune response in this population. Measures towards alleviating chronic inflammation could partially restore NKL T-cell impairment.
- Published
- 2009
- Full Text
- View/download PDF
34. About the role of prohepcidin as an indicator of iron status in dialysis patients.
- Author
-
Eleftheriadis T, Liakopoulos V, Kartsios C, Antoniadi G, Zarogiannis S, Markala D, and Stefanidis I
- Subjects
- Anemia etiology, Biomarkers analysis, Case-Control Studies, Female, Hepcidins, Humans, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic therapy, Male, Reference Values, Renal Dialysis methods, Sensitivity and Specificity, Anemia diagnosis, Antimicrobial Cationic Peptides metabolism, Iron metabolism, Protein Precursors metabolism, Renal Dialysis adverse effects
- Published
- 2008
- Full Text
- View/download PDF
35. Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients.
- Author
-
Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, and Markala D
- Subjects
- Aged, Biomarkers analysis, CD3 Complex, Case-Control Studies, Chronic Disease, Down-Regulation, Female, Flow Cytometry, Humans, Lymphocyte Count, Male, Middle Aged, Receptors, IgG, Renal Dialysis, Inflammation pathology, Kidney Failure, Chronic pathology, Killer Cells, Natural pathology, Receptors, Antigen, T-Cell analysis
- Abstract
Background: Natural killer (NK) cell activity is decreased in hemodialysis (HD) patients. Zeta-chain phosphorylation is an early event that follows the triggering of some NK cell-activating receptors. NK cell zeta-chain is downregulated in patients with cancer due to chronic inflammation. HD is also a chronic inflammatory state. NK cell zeta-chain expression in HD was evaluated., Patients and Methods: Thirty-three HD patients and 30 healthy volunteers were enrolled into the study. The CD3-CD16+ subpopulation was examined, since it corresponds to 90% of all NK cells and has the highest cytotoxicity.NK cell count and zeta-chain mean fluorescence intensity were evaluated with flow cytometry. The inflammatory markers C-reactive protein, IL-6 and tumor necrosis factor-alpha were measured with ELISA., Results: The inflammatory markers were increased in HD patients. NK cell count did not differ between HD patients and healthy volunteers. NK cell zeta-chain mean fluorescence intensity was decreased in the patient group., Conclusions: Chronic inflammation could be responsible for the NK cell zeta- chain downregulation in HD patients, contributing to the decreased NK cell activity., ((c) 2008 S. Karger AG, Basel)
- Published
- 2008
- Full Text
- View/download PDF
36. Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients.
- Author
-
Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, and Markala D
- Subjects
- Aged, C-Reactive Protein metabolism, CD3 Complex metabolism, Chronic Disease, Down-Regulation immunology, Female, Humans, Kidney Failure, Chronic therapy, Lymphocyte Count, Male, Middle Aged, Phosphorylation, Renal Dialysis, Inflammation immunology, Kidney Failure, Chronic immunology, Membrane Proteins metabolism, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
Background: Clinical and experimental data indicate a deficient immune response in hemodialysis (HD) patients. zeta-Chain phosphorylation is an early and central event in the process that follows antigen recognition by the T cell antigen receptor (TCR). T cell zeta-chain is downregulated in many chronic inflammatory states, such as cancer, autoimmune disease and chronic infection. HD is also characterized as a chronic inflammatory state. The aim of the present study was to evaluate T cell zeta-chain expression in HD patients., Patients and Methods: Thirty-three stable HD patients and 30 healthy volunteers were enrolled into the study. T cell count, the percentage of zeta-chain-positive T cells, as well as T cell zeta-chain mean fluorescence intensity (MFI) were evaluated with flow cytometry. The inflammatory markers C-reactive protein, interleukin-6 and tumor necrosis factor-alpha were measured in the serum by means of ELISA., Results: All the evaluated markers of inflammation were increased in HD patients. In these patients, T cell zeta-chain MFI was decreased. CD3-epsilon MFI did not differ between the two groups indicating that among the TCR complex constituents, zeta-chain is selectively downregulated., Conclusions: HD is a state of chronic inflammation. Like in other pathological chronic inflammatory conditions, T cell zeta-chain is downregulated in HD patients. Since zeta-chain plays a key role in the transduction of the signal that follows antigen recognition by the TCR, its downregulation could be responsible for the deficient cellular immune response observed in HD patients., ((c) 2007 S. Karger AG, Basel.)
- Published
- 2008
- Full Text
- View/download PDF
37. Patterns of cell death and cell cycle profiles of cultured WEHI 13 var fibroblasts exposed to eluates of composite resins used for direct and indirect restorations.
- Author
-
Bakopoulou A, Tsiftsoglou A, Galaktidou G, Markala D, Triviai I, and Garefis P
- Subjects
- Analysis of Variance, Animals, Caspase 3 metabolism, Cell Cycle drug effects, Cell Membrane drug effects, Cell Shape drug effects, Cells, Cultured, Dental Restoration, Permanent adverse effects, Enzyme Activation, Flow Cytometry, Mice, Mice, Inbred BALB C, Microscopy, Fluorescence, Cell Death, Composite Resins toxicity, Fibroblasts drug effects
- Abstract
Previous studies have shown that in vitro exposure to single compounds released from composite resins may induce cell death. In the present study the effects of eluates from commercially available composite resins used for direct or indirect restorations were evaluated on the cell cycle progression and type of cell death of cultured WEHI 13 var fibroblasts. Cells exposed to eluates of the materials were assessed for cytotoxicity by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cell death, for cell cycle profiles by flow cytometry, for caspase-3 biochemically and by immunocytochemistry, and for morphological changes by fluorescence microscopy with acridine orange. The direct composite resin eluates induced extensive apoptosis, followed by secondary necrosis. This was accompanied by cell enlargement, micromultinucleation, chromatin disintegration, cell cycle arrest at different phases, and caspase-3 activation. The composites for indirect restorations were much less cytotoxic at all biological end-points investigated. The findings suggest that composite resins used for direct and indirect dental restorations differ in their cytotoxic potential and their ability to affect basic cellular functions. This underlines the impact of improved polymerization with respect to their biologic behavior.
- Published
- 2007
- Full Text
- View/download PDF
38. Association of CD38 expression and diagnostic immunophenotypic score in B cell chronic lymphocytic leukemia.
- Author
-
Kartsios C, Yiannaki E, Eleftheriadis T, Katodritou E, Ditsa M, Zervas K, and Markala D
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD analysis, Biomarkers, Tumor analysis, Female, Glycoproteins analysis, Humans, Immunoglobulin Light Chains analysis, Leukemia, Lymphocytic, Chronic, B-Cell classification, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Male, Middle Aged, Prognosis, ADP-ribosyl Cyclase 1 analysis, Antigens, Neoplasm analysis, B-Lymphocytes chemistry, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Membrane Glycoproteins analysis
- Published
- 2007
- Full Text
- View/download PDF
39. Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.
- Author
-
Theodoridou A, Kartsios C, Yiannaki E, Markala D, and Settas L
- Subjects
- Adalimumab, Antibodies, Monoclonal, Humanized, Arthritis, Rheumatoid drug therapy, Female, Humans, Immunophenotyping, Lymphocyte Subsets drug effects, Lymphocytosis classification, Middle Aged, T-Lymphocytes drug effects, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antibodies, Monoclonal adverse effects, Immunologic Factors adverse effects, Lymphocytosis chemically induced, Neutropenia chemically induced
- Published
- 2006
- Full Text
- View/download PDF
40. Does hepcidin affect erythropoiesis in hemodialysis patients?
- Author
-
Eleftheriadis T, Kartsios C, Liakopoulos V, Antoniadi G, Ditsa M, Papadopoulos C, Anifandis G, Skirta A, Markala D, and Stefanidis I
- Subjects
- Aged, Antimicrobial Cationic Peptides blood, Case-Control Studies, Erythropoiesis drug effects, Erythropoietin administration & dosage, Female, Hematocrit, Hepcidins, Humans, Iron administration & dosage, Iron metabolism, Linear Models, Male, Middle Aged, Protein Precursors blood, Antimicrobial Cationic Peptides physiology, Erythropoiesis physiology, Protein Precursors physiology, Renal Dialysis
- Abstract
Introduction: Prohepcidin is the precursor of hepcidin, a liver-derived peptide involved in iron metabolism by blocking its intestinal absorption and its release by the reticuloendothelial system. Iron overload and inflammation increase hepcidin expression, whereas anemia and hypoxia suppress it. In the present study prohepcidin levels were determined in the serum of hemodialysis (HD) patients and its correlations with iron metabolism markers, C-reactive protein (CRP) and hematocrit (Hct) were assessed., Patients and Methods: Forty-sixHD patients and 22 healthy volunteers were enrolled in the study. Hct, serum prohepcidin, CRP, iron, ferritin, transferrin saturation and transferrin receptors were measured. The weekly erythropoietin dose, last-month intravenous iron dose and the patients' demographics were recorded., Results: In comparison to the healthy volunteers, the HD patients had higher serum ferritin, transferrin receptors and CRP, lower serum iron and similar transferrin saturation and prohepcidin levels. In the patient group prohepcidin levels were negatively correlated with Hct but not with any other of the examined parameters. Multiple linear regression analysis considering age, inflammation, iron adequacy, erythropoietin dose and prohepcidin levels revealed that prohepcidin was the predominant determinant of Hct., Conclusions: Taking into account the low Hct levels in the HD patients of our study, it seems plausible that the prohepcidin levels assessed in this group are inappropriately high. These functionally high prohepcidin levels may be associated with the factors that inhibit erythropoiesis in HD patients. On the other hand, the absence of other expected correlations indicates that further studies are needed in order to definitely clarify this aspect., (Copyright 2006 S. Karger AG, Basel.)
- Published
- 2006
- Full Text
- View/download PDF
41. Can we expect something from prohepcidin measurement in hemodialysis patients?
- Author
-
Eleftheriadis T, Liakopoulos V, Kartsios C, Antoniadi G, Markala D, and Stefanidis I
- Subjects
- Adult, Aged, Aged, 80 and over, Enzyme-Linked Immunosorbent Assay, Erythropoietin administration & dosage, Erythropoietin blood, Female, Hematocrit, Hepcidins, Humans, Inflammation blood, Injections, Subcutaneous, Interleukin-6 blood, Male, Middle Aged, Predictive Value of Tests, Antimicrobial Cationic Peptides blood, Erythropoiesis drug effects, Iron blood, Protein Precursors blood, Renal Dialysis
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.